ESMO TAT 2023 | Challenges of performing neoantigen-specific TIL therapy

Elena Garralda Cabanas, MD, San Raffaele Scientific Institute, Milan, Italy, outlines the two main problems facing research into neoantigen specific tumor infiltrating lymphocyte (TIL) therapy. The process of isolating, expanding, and infusing the patient with TIL therapy without the enrichment of neoantigen-specific cells already takes approximately one month but this is extended to three months with this additional enrichment. The second issue is that patients receiving checkpoint inhibitor therapy have fewer reactive T cells, making it harder to achieve an immunogenic response with neoantigen-specific TIL therapy. This interview took place at the ESMO Targeted Anticancer Therapies (TAT) Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.